Real‐World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy
Authors' conclusion
Consistent with clinical trials, results from this large observational registry suggest that concomitant immunomodulatory drug treatment improves pegloticase persistence.
Study context
- Population
- Patients with gout receiving pegloticase, ACR Rheumatology Informatics System for Effectiveness registry, January 2016 through June 2020median follow-up 14 months
- Participants
- 700 patients
- Exposure
- Concomitant immunomodulatory drug initiation or prevalent treatment vs no immunomodulatory drug, with pegloticase
- Immunomodulatory drug initiatorsn = 91
- Prevalent immunomodulatory drug recipientsn = 33
- Nonrecipientsn = 576reference
- Outcome
- Time to pegloticase discontinuation
Methodological detailsregistry-based (ACR RISE registry), Cox regression controlling for potential confounders
- Registry-based (ACR RISE registry)
- Cox regression controlling for potential confounders
Main finding
As reported in the abstract
Pegloticase discontinuation
Each group vs nonrecipientsAdjusted hazard ratio (95% CI)
Immunomodulatory drug initiators
0.52(0.37–0.75)
Prevalent immunomodulatory drug recipients
0.69(0.42–1.16)
Observational data: associations, not effects.
Safety
Laboratory abnormalities within 180 days
- Uncommon and not higher with concomitant immunomodulatory drug treatment
- <5%
Original publication
Real‐World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy. Arthritis Care Res (Hoboken). Published 23 June 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →